KMDA
Kamada Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$7.61
−1.93%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$7.57
From 52W high−18.26%
Volume49977.00
Market cap$439.18M
P/E (TTM)19.9x
P/S (TTM)2.3x
Div yield4.70%
Key dataOct 19, 2026
Open
$7.57
From 52W high
−18.26%
Volume
49977.00
Market cap
$439.18M
ValuationView details →
P/E (Fwd)
16.5x
EV/EBITDA
9.1x
P/E (TTM)
19.9x
RSI (14)
40.7
MomentumView details →
1D Return
−1.93%
YTD Return
+8.57%
SummaryUpdated Jun 1, 2026
Kamada Ltd. (NASDAQ:KMDA) is an Israeli biopharmaceutical company founded in 1990 and headquartered in Rehovot, Israel. The company went public on NASDAQ in 2013 and has transformed from a single-product dependency into a diversified plasma-derived therapeutics company. Kamada specializes in developing, manufacturing, and commercializing plasma-derived protein therapeutics, primarily targeting rare diseases and immune-related conditions. The company operates through two main business segments: Proprietary Products and Distribution, with a growing focus on the U.S. market which now represents approximately 60-70% of its revenues.
Similar companies
Latest newsMore news →